pubmed-article:19748980 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0085732 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0282498 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0023688 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C1444748 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C1622297 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0389061 | lld:lifeskim |
pubmed-article:19748980 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
pubmed-article:19748980 | pubmed:issue | 7 | lld:pubmed |
pubmed-article:19748980 | pubmed:dateCreated | 2009-9-21 | lld:pubmed |
pubmed-article:19748980 | pubmed:abstractText | Modulation of the host immune system represents a promising therapeutic approach against cancer, including multiple myeloma. Recent findings indicate that the NK group 2D (NKG2D)- and DNAX accessory molecule-1 (DNAM-1)-activating receptors play a prominent role in tumor recognition and elimination by cytotoxic lymphocytes, suggesting that the levels of NKG2D and DNAM-1 ligand expression on tumor cells may be a critical factor to improve the immune response against cancer. In this study, we tested the effect of 17-allylaminogeldanamycin and radicicol, drugs targeting the heat shock protein-90 (HSP-90) chaperone protein and displaying antimyeloma activity, on the expression of NKG2D and DNAM-1 ligands in human myeloma cell lines. We demonstrate that HSP-90 inhibitors are able to up-regulate both MHC class I chain-related (MIC) A and MICB protein surface and mRNA expression in human myeloma cell lines, without any significant effect on the basal expression of the DNAM-1 ligand poliovirus receptor CD155, or induction of nectin-2 and UL16-binding proteins. Activation of the transcription factor heat shock factor-1 by HSP-90 inhibitors is essential for the up-regulation of MICA/MICB expression and knockdown of heat shock factor-1 using small hairpin RNA interference blocks this effect. Moreover, in vitro and in vivo binding of heat shock factor-1 to MICA and MICB promoters indicates that it may enhance NKG2D ligand expression at the transcriptional level. Finally, exposure to HSP-90 inhibitors renders myeloma cells more efficient to activate NK cell degranulation and a blocking Ab specific for NKG2D significantly reduces this effect. Thus, these results provide evidence that targeting NKG2D ligands expression may be an additional mechanism supporting the antimyeloma activity of HSP-90 inhibitors and suggest their possible immunotherapeutic value. | lld:pubmed |
pubmed-article:19748980 | pubmed:language | eng | lld:pubmed |
pubmed-article:19748980 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19748980 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:19748980 | pubmed:month | Oct | lld:pubmed |
pubmed-article:19748980 | pubmed:issn | 1550-6606 | lld:pubmed |
pubmed-article:19748980 | pubmed:author | pubmed-author:CippitelliMar... | lld:pubmed |
pubmed-article:19748980 | pubmed:author | pubmed-author:FiondaCinziaC | lld:pubmed |
pubmed-article:19748980 | pubmed:author | pubmed-author:SantoniAngela... | lld:pubmed |
pubmed-article:19748980 | pubmed:author | pubmed-author:SorianiAlessa... | lld:pubmed |
pubmed-article:19748980 | pubmed:author | pubmed-author:IannittoMaria... | lld:pubmed |
pubmed-article:19748980 | pubmed:author | pubmed-author:MalgariniGiul... | lld:pubmed |
pubmed-article:19748980 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:19748980 | pubmed:day | 1 | lld:pubmed |
pubmed-article:19748980 | pubmed:volume | 183 | lld:pubmed |
pubmed-article:19748980 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:19748980 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:19748980 | pubmed:pagination | 4385-94 | lld:pubmed |
pubmed-article:19748980 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:meshHeading | pubmed-meshheading:19748980... | lld:pubmed |
pubmed-article:19748980 | pubmed:year | 2009 | lld:pubmed |
pubmed-article:19748980 | pubmed:articleTitle | Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. | lld:pubmed |
pubmed-article:19748980 | pubmed:affiliation | Department of Experimental Medicine, Istituto Pasteur-Fondazione Cenci Bolognetti, University of Rome Sapienza, Rome, Italy. | lld:pubmed |
pubmed-article:19748980 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:19748980 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |